BackY-Mabs Therapeutics Overview

Y-Mabs Therapeutics Receivables

Track Y-Mabs Therapeutics's receivables ($16M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$15.74M
↓ 58.81% YoYΔ $-22.48M vs prior year quarter

Peer trimmed avg / median

Loading

Y-Mabs Therapeutics Receivables History

Loading

Y-Mabs Therapeutics vs. peers: Receivables Comparison

Loading

Y-Mabs Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Y-Mabs Therapeutics (YMAB) FAQ

As of the most recent data (June 2025), YMAB shows a receivables of $16M. That compares with $38M in the prior-year period — down 58.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, YMAB's receivables is now $16M (was $38M) — a 58.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Y-Mabs Therapeutics is outperforming or lagging.

Tracking YMAB's receivables over time shows whether Y-Mabs Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $16M That compares with $38M in the prior-year period — down 58.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Y-Mabs Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $16M) with ownership activity and broader fundamentals.

Y-Mabs Therapeutics's receivables is $16M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.